We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Alunbrig

News List

Preliminary NICE ‘no’ for Takeda’s Alunbrig pharmatimes
October 11, 2018
Draft guidelines from the National Institute for Health and Care Excellence do not recommend NHS funding for Takeda’s lung cancer drug Alunbrig.
Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy pharmatimes
September 27, 2018
Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.
Takeda’s Alunbrig beats Pfizer’s Xalkori on PFS in ALK positive NSCLC pharmatimes
July 27, 2018
Takeda’s Alunbrig has beaten Pfizer's Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer.

Previous page 1 2 Next page